Piro Lito

Enid A. Haupt Chair in Therapeutic Research

Piro Lito

Enid A. Haupt Chair in Therapeutic Research
Share
Share
Piro Lito

Lab Phone

646-888-3111
My research is aimed at developing optimal therapies to treat cancers that harbor BRAF or KRAS mutations, as well as at understanding how these proteins affect intracellular signaling and cellular function.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Piro Lito discloses the following relationships and financial interests:

  • AmMax Bio, Inc.
    Professional Services and Activities
  • Biotheryx, Inc.
    Equity; Professional Services and Activities
  • Black Diamond Therapeutics, Inc.
    Professional Services and Activities
  • Boehringer Ingelheim
    Professional Services and Activities
  • Frontier Medicines Corporation
    Equity; Professional Services and Activities
  • Ikena Oncology
    Equity; Professional Services and Activities
  • Menarini Ricerche
    Professional Services and Activities
  • OrbiMed
    Professional Services and Activities
  • PAQ Therapeutics Inc.
    Equity; Professional Services and Activities
  • Repare Therapeutics
    Professional Services and Activities
  • Revolution Medicines
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures